Skip to main content

Advertisement

SpringerLink
Log in

Fibrosis markers in hepatitis C

  • Published:
Current Hepatitis Reports Aims and scope Submit manuscript

Abstract

Significant morbidity and mortality due to chronic hepatitis C infection have led to efforts to identify patients at risk of progressive disease. Current clinical practice relies on liver biopsy as the gold standard for assessing the severity of chronic hepatitis C, but liver biopsy is associated with sampling error and exposes patients to procedural risks and additional health care expenses. Several surrogate markers of fibrosis have now been developed, although they have been validated only in select patient populations and do not accurately differentiate between intermediate stages of fibrosis. Additional studies to determine the clinical utility of noninvasive markers are in progress.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. EASL International Consensus Conference on hepatitis C. Paris, 26-27 February 1999. Consensus statement. J Hepatol 1999, 31(Suppl 1):3–8.

  2. Afdhal NH: The natural history of hepatitis C [review]. Semin Liver Dis 2004, 24(Suppl 2):3–8.

    Article  PubMed  Google Scholar 

  3. Regev A, Berho M, Jeffers LJ, et al.: Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002, 97:2614–2618.

    Article  PubMed  Google Scholar 

  4. Intraobserver with interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology 1994, 20:15-20.

  5. Bedossa P, Dargère P, Paradis V: Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003, 38:1449–1457.

    PubMed  Google Scholar 

  6. Guechot J, Laudat A, Loria A, et al.: Diagnostic accuracy of hyaluronan and type III procollagen amino-terminal peptide serum assays as markers of liver fibrosis in chronic viral hepatitis C evaluated by ROC curve analysis. Clin Chem 1996, 42:558–563.

    PubMed  CAS  Google Scholar 

  7. Leroy V, Monier F, Bottari S, et al.: Circulating matrix metalloproteinases 1, 2, 9 and their inhibitors TIMP-1 and TIMP-2 as serum markers of liver fibrosis in patients with chronic hepatitis C: comparison with PIIINP and hyaluronic acid. Am J Gastroenterol 2004, 99:271–279.

    Article  PubMed  CAS  Google Scholar 

  8. Abe S, Narita R, Hiura M, et al.: Early decrease in serum IV-7S levels during IFN treatment predicts anti-fibrogenic effect in nonresponders with chronic hepatitis C. J Gastroenterol 2004, 39:247–254.

    Article  PubMed  CAS  Google Scholar 

  9. Walsh KM, Timms P, Campbell S, et al.: Plasma levels of matrix metalloproteinase-2 (MMP-2) and tissue inhibitors of metalloproteinases-1 and -2 (TIMP-1 and TIMP-2) as noninvasive markers of liver disease in chronic hepatitis C: comparison using ROC analysis. Dig Dis Sci 1999, 44:624–630.

    Article  PubMed  CAS  Google Scholar 

  10. Murawaki Y, Yamada S, Ikuta Y et al.: Clinical usefulness of serum matrix metalloproteinase-2 concentration in patients with chronic viral liver disease. J Hepatol 1999, 30:1090–1098.

    Article  PubMed  CAS  Google Scholar 

  11. Boeker KHW, Haberkorn CI, Michels D, et al.: Diagnostic potential of circulating TIMP-1 and MMP-2 as markers of liver fibrosis in patients with chronic hepatitis C. Clin Chim Acta 2002, 316:71–81.

    Article  PubMed  CAS  Google Scholar 

  12. Wong VS, Hughes V, Trull A, et al.: Serum hyaluronic acid is a useful marker of liver fibrosis in chronic hepatitis C virus infection. J Viral Hepatitis 1998, 5:187–192.

    Article  CAS  Google Scholar 

  13. McHutchison JG, Blatt LM, De Medina M, et al.: Measurement of serum hyaluronic acid in patients with chronic hepatitis C and its relationship to liver histology. J Gastroenterol Hepatol 2000, 15:945–951.

    Article  PubMed  CAS  Google Scholar 

  14. Körner T, Kropf J, Gressner AM: Serum laminin and hyaluronan in liver cirrhosis: markers of progression with high prognostic value. J Hepatol 1996, 25:684–688.

    Article  PubMed  Google Scholar 

  15. Patel K, Lajoie A, Heaton S, et al.: Clinical use of hyaluronic acid as a predictor of fibrosis change in hepatitis C. J Gastroenterol Hepatol 2003, 18:253–257.

    Article  PubMed  CAS  Google Scholar 

  16. Johansen JS, Christoffersen P, Moller S, et al.: Serum YKL- 40 is increased in patients with hepatic fibrosis. J Hepatol 2000, 32:911–920.

    Article  PubMed  CAS  Google Scholar 

  17. Patel K, Rockey DC: Clinical utility of biomarkers of liver fibrosis. Gastroenterol Hepatol 2006, 1:48–57.

    Google Scholar 

  18. Kanzler S, Baumann M, Schirmacher P, et al.: Prediction of progressive liver fibrosis in hepatitis C infection by serum and tissue levels of transforming growth factor-β. J Viral Hepat 2001, 8:430–437.

    Article  PubMed  CAS  Google Scholar 

  19. Forns X, Ampurdanès S, Llovet JM, et al.: Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002, 36:986–992.

    PubMed  Google Scholar 

  20. Wai C, Greenson JK, Fontana RJ, et al.: A simple noninvasive index can predict both Significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003, 38:518–526.

    Article  PubMed  Google Scholar 

  21. Fix OK: The performance of APRI for the diagnosis of Significant hepatic fibrosis is improved by a simple modification. Paper presented at the 56th Annual Meeting of the American Association for the Study of Liver Diseases. San Francisco, CA; November 11-15, 2005, Abstract 597.

  22. Sud A, Hui JM, Farrell GC, et al.: Improved prediction of fibrosis in chronic hepatitis C using measures of insulin resistance in a probability index. Hepatology 2004, 39:1239–1247.

    Article  PubMed  Google Scholar 

  23. Imbert-Bismut F, Ratziu V, Pieroni L, et al.; MULTIVIRC Group: Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001, 357:1069–1075.

    Article  PubMed  CAS  Google Scholar 

  24. Poynard T, Imbert-Bismut F, Munteanu M, et al.: Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp Hepatol 2004, 3:8–19. This comprehensive overview incorporates a meta-analysis of published studies on the diagnostic utility of the FibroTest-ActiTest (FT-AT) and new statistical analyses that assess the impact of hepatitis C virus genotype and viral load on the performance of FT-AT and compare the performance of FT-AT with other serum fibrosis markers.

    Article  PubMed  Google Scholar 

  25. Poynard T, Munteanu M, Imbert-Bismut F, et al.: Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C. Clin Chem 2004, 50:1344–1355.

    Article  PubMed  CAS  Google Scholar 

  26. Patel K, Gordon SC, Jacobson I, et al.: Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients. J Hepatol 2004, 41:935–942. This study tested and validated the three-marker panel, FIBROSpect II®, which is commercially available in the United States.

    Article  PubMed  CAS  Google Scholar 

  27. Rosenberg WM, Voelker M, Thiel R, et al.; European Liver Fibrosis Group: Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 2004, 127:1704–1713.

    Article  PubMed  Google Scholar 

  28. Ziol M, Handra-Luca A, Kettaneh A, et al.: Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 2005, 41:48–54.

    Article  PubMed  Google Scholar 

  29. Castera L, Vergniol J, Foucher J, et al.: Prospective comparison of transient elastography, FibroTest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005, 128:343–350.

    Article  PubMed  Google Scholar 

  30. Callewaert N, Van Vlierberghe H, Van Hecke A, et al.: Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics. Nat Med 2004, 10:429–434.

    Article  PubMed  CAS  Google Scholar 

  31. Mora R: Diagnostic value of biochemical markers, FibroTest-ActiTest-HCV-FibroSure (FT-AT) compared with serum protein profiling by SELDI-TOF protein chip (STP), for the diagnosis of bridging fibrosis in patients with chronic hepatitis C. Presented at the 55th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, MA; October 29-November 2, 2005, Abstract 810.

  32. Sebastiani G, Vario A, Guido M, et al.: Stepwise combination algorithms of non-invasive markers to diagnose Significant fibrosis in chronic hepatitis C. J Hepatol 2006, 44:686–693.

    Article  PubMed  CAS  Google Scholar 

  33. Adams LA, Bulsara M, Rossi E, et al.: Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem 2005, 51:1867–1873.

    Article  PubMed  CAS  Google Scholar 

  34. Calès P, Oberti F, Michalak S, et al.: A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology 2005, 42:1373–1381.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Gastroenterology, Duke University Medical Center, Duke Clinical Research Institute, 2400 Pratt Street, Room 0311 Terrace Level, 27707, Durham, NC, USA

    Keyur Patel MD

Authors
  1. Carla W. Brady MD, MHS
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John G. McHutchison MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Keyur Patel MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Keyur Patel MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Brady, C.W., McHutchison, J.G. & Patel, K. Fibrosis markers in hepatitis C. Curr hepatitis rep 5, 86–93 (2006). https://doi.org/10.1007/s11901-006-0010-3

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11901-006-0010-3

Keywords

Search

Navigation